Anavex Life Sciences Corp (AVXL)

[nidan7500]

boi568

The first prong is not as obvious as the second. Aside from demonstrating Anavex's commitment to a platform-based pharmaceutical, it also indicates that the company's research shows the best treatment regime correlates according to symptom and biomarker, rather than by disease diagnosis. (Shades of Mayomobile's predictive matrix are appearing to me.) Put another way, I think this means that the company has found the dose-response curve to track symptoms and biomarkers better than diseases. This is consistent with the Anavex position that it has an upstream, platform-based solution acting above specific indications.

Brilliant assessment boi568 and follow up, thank you. The learning process must and will continue from here. IMO, Dr.M. is already working down-along these lines. In the meantime, many patients and their families will be involved in each process step, some may have a longer path than others. This, IMO, is at least civilized clinical-medical science w/an excellent focus with a true clinical knowledge blessing to follow. This is how work gets done. Brilliant leadership is required. We may even see a new CNS disease FDA start to contribute, IMO.

I am not qualified to assess any endpoints yet, but I do recognize a new standard of/for processing excellence . Thanks very much for your work. WGT.